NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
Clinical Trials
12 trialsNCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT02481934 2021-08-20
NK-VS-MM
Hospital Universitario 12 de Octubre
Phase 1 Completed
NCT00858234 2021-04-09
MK-0683-098
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT02100657 2020-10-12
Study of Plitidepsin (AplidinĀ®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
PharmaMar
Phase 1 Completed
NCT00424840 2019-02-01
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
University of Massachusetts, Worcester
Phase 1 Terminated
NCT00560352 2017-03-13
Safety Study of Dasatinib With Bortezomib (VelcadeĀ®) and Dexamethasone for Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Terminated
NCT00111813 2015-05-21
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01462773 2015-01-13
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00985959 2013-12-02
A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT00608907 2012-01-30
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
Millennium Pharmaceuticals, Inc.
Phase 1 Completed